News

Ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (CAS: 144927-57-1) is a heterocyclic compound with the molecular formula C₉H₈ClN₃O₂ and a molecular weight of 225.63 g/mol. Its core structure consists of a pyrrolo[2,3-d]pyrimidine bicycle fused with a chlorine atom at the 4-position and an ethyl ester group at the 5-position. This unique purine-like scaffold — often referred to as a 7‑deazapurine — closely mimics the structure of adenine, the natural ligand of ATP-binding sites in protein kinases, providing an adaptable platform for designing potent inhibitors of various kinases that play crucial regulatory roles in cellular processes [11†L14-L20].

As a key pharmaceutical intermediate, this compound plays an irreplaceable role in the synthesis of several FDA-approved Janus kinase (JAK) inhibitors, including ruxolitinib (for myelofibrosis and polycythemia vera), tofacitinib (for rheumatoid arthritis and ulcerative colitis), and baricitinib (for rheumatoid arthritis and COVID-19) [7†L32-L40]. Beyond JAK inhibitors, pyrrolo[2,3-d]pyrimidine derivatives have been extensively studied as kinase inhibitors targeting a broad spectrum of cancer-related kinases, including FAK, c‑Met/Axl, FLT3/IRAK4, Aurora A, and CSF1R. Recent studies have demonstrated that FAK inhibitors derived from this scaffold achieved an IC₅₀ as low as 0.5 nM with a 61.8% tumor growth inhibition rate in triple‑negative breast cancer xenograft models, outperforming paclitaxel [12†L18-L27]. Dual c‑Met/Axl inhibitors have achieved tumor growth inhibition rates of 98.2% and 87.2% at a dosage of 1 mg/kg in xenograft models [13†L19-L21], while FLT3/IRAK4 inhibitors have shown IC₅₀ values of 1.95 nM against FLT3-WT with low toxicity to normal bone marrow cells [14†L6-L11].

Market demand is closely tied to the global expansion of targeted cancer therapies, the rising prevalence of autoimmune diseases, and the growing need for advanced heterocyclic building blocks in pharmaceutical R&D pipelines. Its production typically involves multi‑step organic synthesis starting from dimethyl malonate, proceeding through alkylation, cyclization, chlorination, oxidation, and esterification steps [7†L12-L24].

Major Market Participants

The global supply system for ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate follows a pattern of specialized pharmaceutical intermediate manufacturers, primarily in China and India, serving both small‑scale R&D and large‑scale industrial production. The compound is commonly supplied as a solid crystalline powder with purity ranging from 97% to ≥98‑99% and must be stored at 2‑8°C under an inert atmosphere to ensure stability [4†L4-L7][15†L5-L8].

Shanghai XinChem Co., Ltd. (XinChem) has established a reliable supply chain for high‑purity ethyl 4‑chloro‑7H‑pyrrolo[2,3‑d]pyrimidine‑5‑carboxylate. Our product meets rigorous specifications — purity ≥98‑99% (HPLC), a crystalline solid form, controlled residual solvents, and strict heavy metal limits — fully complying with global pharmaceutical intermediate standards.

Regional Market Dynamics

Global demand for this pyrrolopyrimidine intermediate shows distinct regional patterns: “North America and Europe lead in JAK inhibitor R&D and targeted cancer therapy development, accounting for the largest share of high‑purity (≥99%) grade consumption. The United States alone hosts numerous pharmaceutical companies developing next‑generation JAK inhibitors for autoimmune diseases and myeloproliferative neoplasms, supported by robust NIH funding and academic oncology research programs. Europe, particularly Germany, Switzerland, and the United Kingdom, maintains a strong presence in kinase inhibitor discovery with strict regulatory requirements under REACH and EMA guidelines.

Asia‑Pacific is the fastest‑growing region, driven by expanding contract research and manufacturing organizations (CROs/CDMOs) in China and India. China has emerged as a dominant manufacturing hub for pharmaceutical heterocyclic intermediates, while India’s rapidly growing generic JAK inhibitor production sector demands increasing volumes of high‑quality intermediates.

Regulatory and Environmental Considerations

Ethyl 4‑chloro‑7H‑pyrrolo[2,3‑d]pyrimidine‑5‑carboxylate (CAS 144927-57-1) requires careful handling as a research chemical. The compound is classified with hazard statements H315 (skin irritation), H319 (serious eye irritation), and H335 (may cause respiratory irritation) [15†L11-L12]. Storage conditions demand an inert atmosphere (nitrogen or argon) and refrigeration at 2‑8°C to prevent decomposition [15†L9-L10].

In the European Union, the compound is subject to REACH regulations; importers and manufacturers must provide Safety Data Sheets (SDS). In the United States, it is regulated under TSCA as a research chemical, and API‑manufacturing customers must adhere to cGMP guidelines (21 CFR Parts 210/211). In China, the compound is listed in the Inventory of Existing Chemical Substances (IECSC) and requires safety production licenses for manufacturing facilities.

Environmentally, the compound is classified as a persistent organic pollutant control substance. Manufacturing generates solvent‑containing waste streams and requires responsible disposal of chlorinated by‑products. Green chemistry efforts focus on optimizing multi‑step synthesis to improve yield, reduce solvent consumption, and develop more sustainable chlorination and cyclization protocols.

Future Outlook

The market outlook for ethyl 4‑chloro‑7H‑pyrrolo[2,3‑d]pyrimidine‑5‑carboxylate is tied to four core drivers: (1) the expanding global market for JAK inhibitors, projected to grow from approximately USD 9‑10 billion in 2024 to USD 18‑25 billion by 2030–2032; (2) the continuing discovery of novel pyrrolopyrimidine-based kinase inhibitors for oncology, inflammation, and infectious diseases; (3) the rapid growth of Asian CRO/CDMO sectors supplying intermediates to global pharmaceutical companies; and (4) increasing investment in targeted cancer therapy and autoimmune disease research worldwide.

Challenges include: raw material availability and cost fluctuations for starting materials (dimethyl malonate, amidine derivatives, phosphorus oxychloride), the need for strict inert‑atmosphere storage and cold‑chain logistics, and competition from alternative heterocyclic scaffolds. Enterprises should focus on securing high‑purity (>99%) supply capabilities, maintaining rigorous quality documentation for pharmaceutical regulatory filings (DMF support for generic JAK inhibitor registration), and building long‑term relationships with API manufacturers, CROs, and research institutions.

Shanghai XinChem Co., Ltd. (XinChem)

As a world‑leading supplier of pharmaceutical intermediates and heterocyclic building blocks, Shanghai XinChem Co., Ltd. (XinChem) has always focused on the innovative needs of the targeted therapeutics, oncology drug discovery, and anti‑inflammatory API industries. Relying on core advantages in multi‑step heterocyclic synthesis, purification, and quality assurance, we provide high‑quality Ethyl 4‑chloro‑7H‑pyrrolo[2,3‑d]pyrimidine‑5‑carboxylate (CAS 144927-57-1) to global customers.

1. Technical Advantages

High Purity & Consistency: Our product achieves purity ≥98‑99% (HPLC), with white to off‑white crystalline powder appearance, molecular weight 225.63 g/mol, and MDL number MFCD11518913.
Low Impurity Profile: Strict control of residual solvents, water content (<0.5%), and heavy metals (≤10 ppm, ICH Q3D compliant). A moisture specification of 0.5% Max is standard [9†L5-L6].
Batch‑to‑Batch Uniformity: Rigorous analytical testing ensures consistent quality across all production lots.

2. Product Advantages

Versatile Heterocyclic Scaffold: Directly used in the synthesis of ruxolitinib, tofacitinib, and baricitinib — three FDA‑approved JAK inhibitors with combined annual sales exceeding USD 5‑8 billion [7†L32-L40].
Reactive Chlorine Position: The C‑4 chlorine enables efficient nucleophilic aromatic substitution with amine nucleophiles, allowing rapid SAR exploration for kinase inhibitor optimization.
Stable Ethyl Ester Protection: The C‑5 ethyl carboxylate group provides orthogonal protection, facilitating selective modification and deprotection sequences.
Flexible Packaging: 5g, 10g, 25g, 50g, 100g, 500g glass bottles (R&D); 1kg HDPE containers (pilot); 5kg, 10kg, 25kg fiber drums (industrial). Full custom packaging available.
Reliable Supply Chain: Annual capacity 100‑500 kg, with dedicated cold‑chain warehousing (2‑8°C, inert atmosphere) and just‑in‑time delivery.

3. Application Fields

Pharmaceutical Intermediates: Synthesis of JAK inhibitors (ruxolitinib, tofacitinib, baricitinib); development of next‑generation JAK1‑selective and TYK2 inhibitors.
Targeted Cancer Therapeutics: Key building block for FAK, c‑Met/Axl, FLT3/IRAK4, Aurora A, and CSF1R kinase inhibitors — each representing validated or emerging oncology targets with extensive clinical pipelines.
Anti‑Inflammatory & Autoimmune APIs: Intermediate for drug candidates targeting rheumatoid arthritis, psoriasis, ulcerative colitis, and other autoimmune disorders.
Heterocyclic Library Synthesis: Core scaffold for medicinal chemistry campaigns, structure‑activity relationship (SAR) studies, and hit‑to‑lead optimization in kinase inhibitor drug discovery.
Antimicrobial Research: As the pyrrolo[2,3‑d]pyrimidine scaffold demonstrates broad‑spectrum bioactivity, ongoing research explores its application in antibacterial, antifungal, and antiviral agent development [10†L11-L22].

4. Service Support

Our technical team provides impurity profiling (by HPLC, LC‑MS), custom purification, and regulatory documentation (COA, TDS, MSDS, REACH compliance, TSCA certification, DMF support for pharmaceutical customers). We offer cold‑chain logistics, custom packaging, and synthesis of analog derivatives upon request.

5. Why Choose XinChem

Professionalism: 20+ years in the pharmaceutical intermediate and heterocyclic synthesis industry.
Flexibility: Tailored to customer purity and packaging requirements.
Cost‑effectiveness: High quality at competitive prices.

Post time: May-17-2026

A Key Intermediate for JAK Inhibitors & Targeted Cancer Therapeutics: Ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (CAS 144927-57-1)